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The results of the China Antihypertensive Trial in Acute 
Ischemic Stroke (CATIS) study were presented last month at 
the 2013 American Heart Association Scientific Meeting and 
simultaneously published in the Journal of the American 
Medical Association [1]. The CATIS study was a multicen-
ter, controlled, randomized study that aimed to assess the 
effects of blood pressure reduction during the acute phase of 
ischemic stroke on death and major disability at 14 days and 
3 months after the episode. The stroke was confirmed by 
brain CT or MRI and systolic blood pressure levels between 
140-220 mmHg were required to enter the study. About half 
of screened patients with an acute ischemic stroke and hyper-
tension fulfilled all inclusion/exclusion criteria and entered 
the study (2,038 out of 4,071).  
Study participants were randomly assigned to receive or 
not antihypertensive therapy within 48 hours of stroke onset. 
In particular, a graded blood pressure reduction was aimed in 
the active group targeting a 10-25% reduction during the 
first study day and blood pressure control during the first 
week post-randomization. In contrast, no antihypertensive 
therapy was given in the control group and previous anti-
hypertensive medication was discontinued during the acute 
phase of stroke. After the first week, all patients received 
antihypertensive therapy to achieve blood pressure control 
(<140/90 mmHg).  
Blood pressure was significantly reduced in both groups 
during the first 24h post-randomization; however, the reduc-
tion was significantly greater in the active compared to the 
control group (21.8 versus 12.7 mmHg; between group dif-
ference: 9.1 mmHg; 95% CI: 8.1-10.2; p<0.001). Similarly, 
blood pressure levels were significantly lower in the active 
group at 7 days post-randomization (between group differ-
ence 9.3 mmHg; 95% CI: 8.4-10.1; p<0.001). The primary 
outcome (death or major disability at 14 days or hospital 
discharge) was identical in the two groups (odds ratio: 1.00; 
95% CI: 0.88-1.14; p=0.98). The secondary outcome (death  
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or major disability at 3 months post-randomization) was also 
the same (odds ratio: 0.99; 95% CI: 0.86-1.15; p=0.93), de-
spite lower blood pressure values in the active group.  
Subgroup analysis did not reveal any significant differ-
ences between the two groups on study outcomes. Blood 
pressure reduction during the acute phase of stroke seemed 
to confer a significant benefit only in one subgroup of pa-
tients: those who received antihypertensive therapy after the 
first 24h of stroke onset (odds ratio: 0.73; 95% CI: 0.55-
0.97; p=0.03). It has to be noted however that the findings of 
the subgroup analysis should always interpreted with cau-
tion, and be considered rather as hypothesis generating than 
conclusive. 
The results of the CATIS study add more gas on the de-
bate about the management of elevated blood pressure dur-
ing the acute phase of an ischemic stroke. Current guidelines 
recommend blood pressure lowering in acute ischemic stroke 
only when blood pressure levels are above 220/120 mmHg 
[2]. However, such patients represent a minority, with less of 
1% of patients admitted for stroke [3]. Therefore, a therapeu-
tic strategy for the vast majority of stroke patients with ele-
vated blood pressure is of utmost importance for practicing 
clinicians. 
Available data in this field is unfortunately limited and 
inconclusive. About a decade ago, the Acute Candesartan 
Cilexitil Therapy in Stroke Survivors (ACCESS) study cre-
ated a lot of enthusiasm [4]. A significantly lower rate of 
vascular events and all-cause mortality at 12 months was 
observed with candesartan compared to placebo (odds ratio: 
0.475; 95% CI: 0.252-0.895), and the study was prematurely 
terminated when almost 350 patients were randomized in-
stead of the projected 500 patients. 
The ACCESS study questioned the negative findings of 
the Intravenous Nimodipine West European Stroke Trial 
(INWEST) [5], and set the basis for the conduction of a 
larger study, the Scandinavian Candesartan Acute Stroke 
Trial (SCAST). In the latter study, candesartan was com-
pared to placebo in more than 2,000 patients with acute 
stroke, either ischemic or hemorrhagic [6]. Unfortunately, 
the great expectations generated by the ACCESS study were 
Antihypertensives in Acute Stroke The Open Hypertension Journal, 2014, Volume 6    11 
not fulfilled. There was no significant difference in the out-
come between the active and the placebo group of the trial. 
In the meantime, two other smaller studies were pub-
lished. The Controlling Hypertension and Hypotension Im-
mediately Post-Stroke (CHHIPS), a placebo-controlled, ran-
domized study of 179 patients with acute stroke compared 
the effects of labetalol, lisinopril, and placebo [7]. No sig-
nificant differences between the active and the comparison 
groups were observed, apart from a marginal benefit in mor-
tality at 3 months post-stroke (hazard ratio: 0.40; 95% CI: 
0.2-1.0; p=0.05). The Continue or Stop Post-Stroke Anti-
hypertensives Collaborative Study (COSSACS) compared 
the effects of continuation or withdrawal of prior antihyper-
tensive therapy in 763 patients with an acute mild stroke [8]. 
Continuation of antihypertensive therapy did not confer any 
benefit in mortality or disability. 
Taken together, the findings of the CATIS trial combined 
with the findings of previous trials point towards a neutral 
effect of antihypertensive therapy during the acute phase of 
an ischemic stroke. Whether the time of therapy initiation 
(>24h from stroke onset) or other yet unidentified factors 
play a role and might identify patient subgroups who will 
benefit from antihypertensive therapy remains to be clarified 
by future research. Until then, the ‘non-detrimental – non-
beneficial’ effect of antihypertensive therapy suggests the 
individualization of management during the acute stroke by 
treating physicians.  
CONFLICT OF INTEREST 
The author(s) confirm that this article content has no con-




[1] He J, Zhang Y, Xu T, et al. for the CATIS Investigators. Effects of 
immediate blood pressure reduction on death and major disability 
in patients with acute ischemic stroke. JAMA 2013; 311(6): 575-6. 
[2] Jauch EC, Saver JL, Adams HP Jr, et al. American Heart Associa-
tion Stroke Council; Council on Cardiovascular Nursing; Council 
on Peripheral Vascular Disease; Council on Clinical Cardiology. 
Guidelines for the early management of patients with acute 
ischemic stroke: a guideline for healthcare professionals from the 
American Heart Association/American Stroke Association. Stroke 
2013; 44: 870-947. 
[3] Qureshi AI, Ezzeddine MA, Nasar A, et al. Prevalence of elevated 
blood pressure in 563,704 adult patients with stroke presenting to 
the ED in the United States. Am J Emerg Med 2007; 25: 32-38.  
[4] Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: 
evaluation of acute candesartan cilexitil therapy in stroke survivors. 
Stroke 2003; 34: 1699-703. 
[5] Wahlgren NG, MacMahon DG, DeKeyser J, Indrdavik B, Ryman 
T. Intravenous Nimodipine West European Stroke Trial (INWEST) 
of nimodipine in the treatment of acute ischaemic stroke. Cere-
brovasc Dis 1994; 4: 204-10. 
[6] Sandset EC, Bath PM, Boysen G, et al. SCAST Study Group. The 
angiotensin-receptor blocker candesartan for treatment of acute 
stroke (SCAST): a randomised, placebo-controlled, double-blind 
trial. Lancet 2011; 377: 741-50. 
[7] Potter JF, Robinson TG, Ford GA, et al. Controlling Hypertension 
and Hypotension Immediately Post-Stroke (CHHIPS): a random-
ised, placebo-controlled, double-blind pilot trial. Lancet Neurol 
2009; 8: 48-56. 
[8] Robinson TG, Potter JF, Ford GA, et al. COSSACS Investigators. 
Effects of antihypertensive treatment after acute stroke in the Con-
tinue or Stop Post-Stroke Antihypertensives Collaborative Study 
(COSSACS): a prospective, randomised, open, blinded-endpoint 
trial. Lancet Neurol 2010; 9: 767-75. 
 
 
Received: January 20, 2014 Revised: January 24, 2014 Accepted: February 02, 2014 
© Tziomalos et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/-
licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
